Jarrett Failing, MD, of the Mayo Clinic, discusses his study data, which show some agreement between the expression of human leukocyte antigens in primary non–small cell lung cancer with brain metasta...
John N. Lukens, MD, of the Hospital of the University of Pennsylvania, discusses his finding that taking antibiotics within 3 months of starting treatment with immune checkpoint inhibitors may lead to...
Christopher B. Cole, MD, PhD, of the National Cancer Institute, discusses findings from a phase I study of intraperitoneal monocytes activated by interferons alpha and gamma in patients with ovarian c...
Kevin Tyan, of Kinnos, and currently a medical school student at Harvard University, discusses his study findings, which showed that patients with melanoma who are treated with immunotherapy had a sig...
Jacob J. Adashek, DO, of the University of South Florida and Moffitt Cancer Center, discusses data on combining immunoregulatory inhibition and targeted gene therapy, which may offer patients better o...
Martin McCarter, MD, of the University of Colorado Denver, discusses the recent strides in surgical oncology, how the role of surgery has changed, and what lies ahead for this staple of cancer therapy...
Philippa G. Corrie, PhD, of Cambridge University Hospitals NHS Foundation Trust, discusses a review of 2,322 patients with metastatic melanoma receiving first-line immune checkpoint inhibitors as stan...
Luis I. Ruffolo, MD, of the University of Rochester, discusses preclinical studies showing that semaphorin 4D blockade may sensitize pancreatic tumors to chemoimmunotherapy combinations (Abstract 26).
Dario Vignali, PhD, of the University of Pittsburgh and UPMC Hillman Cancer Center, summarizes his Keynote Address, which covered what drives systemic immune dysfunction in patients with cancer, what ...
Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, summarizes a session she co-chaired on utilizing the immune system in neoadjuvant trials to treat me...